Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
Rory McCullochChiara RusconiToby A EyreRebecca FrewinNeil PhillipsDavid L TuckerFrancesca M QuagliaAnnabel McMillanJonathan LambertNicola CrosbieSimon RulePublished in: British journal of haematology (2020)
Patients with mantle cell lymphoma progressing on Bruton's tyrosine kinase inhibitor (BTKi) have very poor prognosis and there is currently no standard of care. In this retrospective cohort study, patients progressing on BTKi received R-BAC (rituximab, bendamustine, cytarabine). Overall response rate was 83% (complete response 60%) and 31% were bridged to allogeneic stem cell transplant (alloSCT). Median progression-free survival was 10.1 months (95% confidence interval (CI) 6·9-13·3) and median overall survival was 12·5 months (95% CI 11·0-14·0). In those consolidated with alloSCT only one patient relapsed. R-BAC demonstrates a high response rate in the post-BTKi setting and in transplant eligible patients is an effective bridge to alloSCT.
Keyphrases
- poor prognosis
- end stage renal disease
- free survival
- stem cells
- acute myeloid leukemia
- ejection fraction
- newly diagnosed
- acute lymphoblastic leukemia
- healthcare
- diffuse large b cell lymphoma
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- stem cell transplantation
- high dose
- hodgkin lymphoma
- multiple myeloma
- low dose
- patient reported outcomes
- mesenchymal stem cells
- case report
- smoking cessation
- chronic lymphocytic leukemia